Comparison of Scheduled and Episodic Treatment Strategies of Infliximab in Crohn’s Disease

Gastroenterology - United Kingdom
doi 10.1053/j.gastro.2003.11.014
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Minimization Analysis of Infliximab Versus Adalimumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Subtherapeutic Concentrations of Infliximab and Adalimumab Are Associated With Increased Disease Activity in Crohn’s Disease

Therapeutic Advances in Gastroenterology
Gastroenterology
2018English

Exclusive Enteral Nutrition Versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease

Gastroenterology Research and Practice
HepatologyGastroenterology
2017English

Individualized Treatment With Infliximab Therapy in Children With Crohn’s Disease Support Shorter Time Intervals Between Infusions

Journal of Drug Assessment
2012English

Infliximab Treatment Time and the Mucosal Healing Effect in Pediatric Patients With Severe Crohn’s Disease – Own Experience

Przeglad Gastroenterologiczny
Gastroenterology
2012English

Treatment Perspectives in Crohn’s Disease

Digestion
Gastroenterology
2018English

Prm142 - Quantitative Benefit-Risk Modelling of Biosimilars: A Case Study of Infliximab in Crohn’s Disease.

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Dietary Treatment of Active Crohn’s Disease

Nursing standard (Royal College of Nursing (Great Britain) : 1987)
Medicine
1990English

Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy